255 related articles for article (PubMed ID: 21558621)
1. CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.
Tran L; Huitema AD; van Rijswijk MH; Dinant HJ; Baars JW; Beijnen JH; Vogel WV
Hum Antibodies; 2011; 20(1-2):29-35. PubMed ID: 21558621
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis.
Tran L; Vogel WV; Sinaasappel M; Muller S; Baars JW; van Rijswijk M; Dinant HJ; Beijnen JH; Huitema AD
Hum Antibodies; 2011; 20(1-2):7-14. PubMed ID: 21558619
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD
Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
5. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
6. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy.
Walsh CA; Fearon U; FitzGerald O; Veale DJ; Bresnihan B
Clin Exp Rheumatol; 2008; 26(4):656-8. PubMed ID: 18799100
[TBL] [Abstract][Full Text] [Related]
7. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.
Kavanaugh A; Rosengren S; Lee SJ; Hammaker D; Firestein GS; Kalunian K; Wei N; Boyle DL
Ann Rheum Dis; 2008 Mar; 67(3):402-8. PubMed ID: 17644541
[TBL] [Abstract][Full Text] [Related]
8. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
Shaw T; Quan J; Totoritis MC
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
[No Abstract] [Full Text] [Related]
9. B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.
Bruijnen S; Tsang-A-Sjoe M; Raterman H; Ramwadhdoebe T; Vugts D; van Dongen G; Huisman M; Hoekstra O; Tak PP; Voskuyl A; van der Laken C
Arthritis Res Ther; 2016 Nov; 18(1):266. PubMed ID: 27863504
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
[TBL] [Abstract][Full Text] [Related]
11. B-cell: a logical target for treatment of rheumatoid arthritis.
Youinou P; Jamin C; Saraux A
Clin Exp Rheumatol; 2007; 25(2):318-28. PubMed ID: 17543163
[TBL] [Abstract][Full Text] [Related]
12. [Anti-CD20 antibody therapy for inflammatory immune diseases].
Tanaka Y
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1801-6. PubMed ID: 17037318
[No Abstract] [Full Text] [Related]
13. The anti-CD20 antibody rituximab reduces the Th17 cell response.
van de Veerdonk FL; Lauwerys B; Marijnissen RJ; Timmermans K; Di Padova F; Koenders MI; Gutierrez-Roelens I; Durez P; Netea MG; van der Meer JW; van den Berg WB; Joosten LA
Arthritis Rheum; 2011 Jun; 63(6):1507-16. PubMed ID: 21400475
[TBL] [Abstract][Full Text] [Related]
14. The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis.
Gamonet C; Deschamps M; Marion S; Herbein G; Chiocchia G; Auger I; Saas P; Ferrand C; Toussirot E
Rheumatology (Oxford); 2015 Sep; 54(9):1744-5. PubMed ID: 26117335
[No Abstract] [Full Text] [Related]
15. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.
Rehnberg M; Amu S; Tarkowski A; Bokarewa MI; Brisslert M
Arthritis Res Ther; 2009; 11(4):R123. PubMed ID: 19686595
[TBL] [Abstract][Full Text] [Related]
17. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity.
Kormelink TG; Tekstra J; Thurlings RM; Boumans MH; Vos K; Tak PP; Bijlsma JW; Lafeber FP; Redegeld FA; van Roon JA
Ann Rheum Dis; 2010 Dec; 69(12):2137-44. PubMed ID: 20679475
[TBL] [Abstract][Full Text] [Related]
18. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
Muylle K; Flamen P; Vugts DJ; Guiot T; Ghanem G; Meuleman N; Bourgeois P; Vanderlinden B; van Dongen GA; Everaert H; Vaes M; Bron D
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1304-14. PubMed ID: 25792453
[TBL] [Abstract][Full Text] [Related]
19. Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis.
Laverman P; van der Geest T; Terry SY; Gerrits D; Walgreen B; Helsen MM; Nayak TK; Freimoser-Grundschober A; Waldhauer I; Hosse RJ; Moessner E; Umana P; Klein C; Oyen WJ; Koenders MI; Boerman OC
J Nucl Med; 2015 May; 56(5):778-83. PubMed ID: 25858044
[TBL] [Abstract][Full Text] [Related]
20. [Rituximab treatment of rheumatoid arthritis: new evidence].
Nasonov EL
Ter Arkh; 2009; 81(6):82-91. PubMed ID: 19663200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]